通过准CDK2和EGFR-ERK信号传导,具有协同作用的抗癌作用
Jinhuan Wu1,2, Yuping Chen1,2, Rui Li1,2
1Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
循环素依赖激酶2 (CDK2) 通过激活USP37来调节ERK通路,USP37稳定ERK1/2,促进癌细胞的增殖. 结合CDK1/2和EGFR抑制剂提供了一个协同作用的抗癌策略.
科学领域:
- 分子生物学分子生物学
- 癌症信号通路 癌症信号通路
- 细胞调节 细胞调节 细胞调节
背景情况:
- 皮表皮生长因子受体 (EGFR) -RAS-ERK信号通路对于细胞生存,生长和增殖至关重要.
- 异常激活EGFR-RAS-ERK通路是许多癌症的标志,驱动瘤发生.
- 了解这种途径的调节者是开发有效癌症疗法的关键.
研究的目的:
- 为了确定ERK路径的新型调节者.
- 阐明CDK2影响ERK信号传输的机制.
- 探索向CDK2和EGFR在癌症中的治疗潜力.
主要方法:
- 研究了CDK2,USP37和ERK1/2.2.之间的相互作用.
- 使用生物化学测试来确定CDK2酸化在USP37二维基酶 (DUB) 活性中的作用.
- 评估了USP37对ERK1/2稳定性和癌细胞增殖的影响.
- 在患者衍生异种移植 (PDX) 模型中评估了结合CDK1/2和EGFR抑制剂的协同抗癌效应.
主要成果:
- 通过其与USP37.7的相互作用,CDK2被确定为ERK通路的新型调节者.
- CDK2可化USP37,增强其二维基因酶活性.
- USP37可对ERK1/2进行二氧化和稳定,从而增加癌细胞的增殖.
- 结合CDK1/2和EGFR抑制通过降低ERK1/2稳定性和PDX模型中的活性来证明协同作用的抗癌效应.
结论:
- CDK2通过激活USP37促进癌细胞增殖,USP37稳定了ERK1/2.2.
- 针对CDK1/2和EGFR同时呈现出对癌症的一种有前途的组合疗法.
- 这种双重向策略提高了杀死癌细胞的效率,并可能减少与治疗相关的副作用.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
